Global RNA-based Therapeutics and Vaccines Industry

Global RNA-based Therapeutics and Vaccines Industry

  • April 2021 •
  • 147 pages •
  • Report ID: 6043219 •
  • Format: PDF
Abstract:
- Global RNA-based Therapeutics and Vaccines Market to Reach $499 Million by 2027
- Amid the COVID-19 crisis, the global market for RNA-based Therapeutics and Vaccines estimated at US$14.7 Million in the year 2020, is projected to reach a revised size of US$499 Million by 2027, growing at aCAGR of 65.5% over the period 2020-2027. RNA-based Therapeutics, one of the segments analyzed in the report, is projected to record 68.1% CAGR and reach US$372.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the RNA-based Vaccines segment is readjusted to a revised 59.2% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $4.5 Million, While China is Forecast to Grow at 62% CAGR
- The RNA-based Therapeutics and Vaccines market in the U.S. is estimated at US$4.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$76.6 Million by the year 2027 trailing a CAGR of 62% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 59.2% and 55.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 43.7% CAGR.

- Select Competitors (Total 41 Featured) -
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics, Inc.
  • Moderna, Inc.
  • Quark Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Sylentis S.A.